Artículo
Labeur, M.; Theodoropoulou, M.; Sievers, C.; Paez-Pereda, M.; Castillo, V.; Arzt, E.; Stalla, G.K. "New aspects in the diagnosis and treatment of cushing disease" (2006) Frontiers of Hormone Research. 35:169-178
Estamos trabajando para incorporar este artículo al repositorio
Consulte la política de Acceso Abierto del editor
Abstract:
Cushing disease which is caused by the excessive production of ACTH is a rare and complex endocrine disorder that still represents a major challenge for the physician in terms of accurate diagnosis and efficient treatment. Diagnosing Cushing syndrome and its etiology is an elaborate procedure and no single test is sensitive and specific enough to provide sufficient accuracy. Therefore, an ordered cascade of tests is necessary recommended by a consensus statement in 2002. The proposed diagnostic algorithm will be summarized in the following section. In the absence of efficient drug therapy, transsphenoidal resection of the pituitary adenoma is the treatment of choice for the reduction of ACTH secretion. However, not all patients can be cured by surgery. In the present article, we examine recent studies that have investigated the therapeutic potential of new generations of drugs for the treatment of Cushing disease such as cabergoline and SOM230. The role of nuclear receptors: retinoic acid receptors and peroxisome proliferator-activated receptor-γ as new approaches for treating pituitary tumors is also discussed. Copyright © 2006 S. Karger AG.
Registro:
| Documento: | Artículo |
| Título: | New aspects in the diagnosis and treatment of cushing disease |
| Autor: | Labeur, M.; Theodoropoulou, M.; Sievers, C.; Paez-Pereda, M.; Castillo, V.; Arzt, E.; Stalla, G.K. |
| Filiación: | Max-Planck-Institute of Psychiatry, Munich, Germany Affectis Pharmaceuticals, Munich, Germany Facultad de Ciencias Veterinarias, UBA, Buenos Aires, Argentina Laboratorio de Fisiología Y Biología Molecular, FCEN, UBA, Buenos Aires, Argentina Internal Medicine, Endocrinology and Clinical Chemistry, Max-Planck-Institute of Psychiatry, Kraepelinstrasse 10, 80804 Munich, Germany |
| Palabras clave: | dopamine receptor stimulating agent; drug derivative; ligand; peroxisome proliferator activated receptor gamma; retinoic acid; somatostatin; algorithm; animal; conference paper; Cushing disease; differential diagnosis; human; Algorithms; Animals; Diagnosis, Differential; Dopamine Agonists; Humans; Ligands; Pituitary ACTH Hypersecretion; PPAR gamma; Somatostatin; Tretinoin |
| Año: | 2006 |
| Volumen: | 35 |
| Página de inicio: | 169 |
| Página de fin: | 178 |
| DOI: | http://dx.doi.org/10.1159/000094325 |
| Título revista: | Frontiers of Hormone Research |
| Título revista abreviado: | Front. Horm. Res. |
| ISSN: | 03013073 |
| CAS: | retinoic acid, 302-79-4; somatostatin, 38916-34-6, 51110-01-1; Dopamine Agonists; Ligands; PPAR gamma; Somatostatin, 51110-01-1; Tretinoin, 302-79-4 |
| Registro: | https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_03013073_v35_n_p169_Labeur |
Referencias:
- Arnaldi, G., Diagnosis and complications of Cushing's syndrome: A consensus statement (2003) J Clin Endocrinol Metab, 88, pp. 5593-5602
- Labeur, M., New perspectives in the treatment of Cushing's syndrome (2004) Curr Drug Targets Immune Endocr Metabol Disord, 4, pp. 335-342
- Findling, J.W., Raff, H., Aron, D.C., The low-dose dexamethasone suppression test: A reevaluation in patients with Cushing's syndrome (2004) J Clin Endocrinol Metab, 89, pp. 1222-1226
- Papanicolaou, D.A., Nighttime salivary cortisol: A useful test for the diagnosis of Cushing's syndrome (2002) J Clin Endocrinol Metab, 87, pp. 4515-4521
- Pacak, K., Eisenhofer, G., Goldstein, D.S., Functional imaging of endocrine tumors: Role of positron emission tomography (2004) Endocr Rev, 25, pp. 568-580
- Ben-Jonathan, N., Dopamine: A prolactin-inhibiting hormone (1985) Endocr Rev, 6, pp. 564-589
- Stack, J., Surprenant, A., Dopamine actions on calcium currents, potassium currents and hormone release in rat melanotrophs (1991) J Physiol, 439, pp. 37-58
- De Camilli, P., Macconi, D., Spada, A., Dopamine inhibits adenylate cyclase in human prolactin-secreting pituitary adenomas (1979) Nature, 278, pp. 252-254
- Colao, A., Annunziato, L., Lombardi, G., Treatment of prolactinomas (1998) Ann Med, 30, pp. 452-459
- Miller, J.W., Crapo, L., The medical treatment of Cushing's syndrome (1993) Endocr Rev, 14, pp. 443-458
- Pivonello, R., Dopamine receptor expression and function in corticotroph pituitary tumors (2004) J Clin Endocrinol Metab, 89, pp. 2452-2462
- Lamberts, S.W., Uitterlinden, P., Klijn, J.M., The effect of the long-acting somatostatin analogue SMS 201-995 on ACTH secretion in Nelson's syndrome and Cushing's disease (1989) Acta Endocrinol, 120, pp. 760-766. , Copenh
- Von Werder, K., Muller, O.A., Stalla, G.K., Somatostatin analogs in ectopic corticotropin production (1996) Metabolism, 45 (1 SUPPL.), pp. 129-131
- Stalla, G.K., Octreotide exerts different effects in vivo and in vitro in Cushing's disease (1994) Eur J Endocrinol, 130, pp. 125-131
- Holland, L.J., The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5 (2005) Eur J Endocrinol, 152, pp. 645-654
- Nielsen, S., Expression of somatostatin receptors on human pituitary adenomas in vivo and ex vivo (2001) J Endocrinol Invest, 24, pp. 430-437
- Bruns, C., SOM230: A novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile (2002) Eur J Endocrinol, 146, pp. 707-716
- Silva, A.P., Regulation of CRH-induced secretion of ACTH and corticosterone by SOM230 in rats (2005) Eur J Endocrinol, 153, pp. R7-R10
- Chambon, P., A decade of molecular biology of retinoic acid receptors (1996) FASEB J, 10, pp. 940-954
- Zhang, X.K., Retinoid X receptor is an auxiliary protein for thyroid hormone and retinoic acid receptors (1992) Nature, 355, pp. 441-446
- Paez-Pereda, M., Retinoic acid prevents experimental Cushing syndrome (2001) J Clin Invest, 108, pp. 1123-1131
- Heaney, A.P., Functional PPAR-gamma receptor is a novel therapeutic target for ACTH-secreting pituitary adenomas (2002) Nat Med, 8, pp. 1281-1287
- Heaney, A.P., Fernando, M., Melmed, S., PPAR-gamma receptor ligands: Novel therapy for pituitary adenomas (2003) J Clin Invest, 111, pp. 1381-1388
- Ambrosi, B., Effects of chronic administration of PPAR-gamma ligand rosiglitazone in Cushing's disease (2004) Eur J Endocrinol, 151, pp. 173-178
Citas:
---------- APA ----------
Labeur, M., Theodoropoulou, M., Sievers, C., Paez-Pereda, M., Castillo, V., Arzt, E. & Stalla, G.K. (2006) . New aspects in the diagnosis and treatment of cushing disease. Frontiers of Hormone Research, 35, 169-178.http://dx.doi.org/10.1159/000094325
---------- CHICAGO ----------
Labeur, M., Theodoropoulou, M., Sievers, C., Paez-Pereda, M., Castillo, V., Arzt, E., et al. "New aspects in the diagnosis and treatment of cushing disease" . Frontiers of Hormone Research 35 (2006) : 169-178.http://dx.doi.org/10.1159/000094325
---------- MLA ----------
Labeur, M., Theodoropoulou, M., Sievers, C., Paez-Pereda, M., Castillo, V., Arzt, E., et al. "New aspects in the diagnosis and treatment of cushing disease" . Frontiers of Hormone Research, vol. 35, 2006, pp. 169-178.http://dx.doi.org/10.1159/000094325
---------- VANCOUVER ----------
Labeur, M., Theodoropoulou, M., Sievers, C., Paez-Pereda, M., Castillo, V., Arzt, E., et al. New aspects in the diagnosis and treatment of cushing disease. Front. Horm. Res. 2006;35:169-178.http://dx.doi.org/10.1159/000094325
